Last updated on July 2019

Study of Efficacy Safety Tolerability Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody CFZ533 in Kidney Transplant Recipients


Brief description of study

The purpose of this study is to investigate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of three CFZ533 dose regimens in kidney transplant recipients.

This study will allow assessment of the ability of CFZ533 to replace Calcineurin inhibitors (CNIs) in terms of anti-rejection efficacy, while providing better renal function with a better safety and tolerability profile. Results of this study will be used to inform the CFZ533 dose and regimen selection for investigation in later phases of clinical development.

Clinical Study Identifier: NCT03663335

Find a site near you

Start Over

Novartis Investigative Site

Chicago, IL United States
  Connect »

Novartis Investigative Site

Kansas City, KS United States
  Connect »

Novartis Investigative Site

Detroit, MI United States
  Connect »

Novartis Investigative Site

Cincinnati, OH United States
  Connect »

Novartis Investigative Site

Charleston, SC United States
  Connect »

Novartis Investigative Site

Seattle, WA United States
  Connect »

Novartis Investigative Site

L'Hospitalet de Llobregat, Spain
  Connect »

Novartis Investigative Site

Manchester, United Kingdom
  Connect »